Park DW, Kwon O, Jang JS, et al. - Researchers undertook this multicenter trial to evaluate ticagrelor's (potent P2Y12 inhibitor) safety and efficacy in East Asian populations. They randomly (1:1) allocated 800 Korean patients hospitalized for acute coronary syndromes with or without ST elevation and intended for invasive management to receive ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (600 mg loading dose, 75 mg daily thereafter). At 12 months, the participants were analyzed to determine clinically significant bleeding (a composite of major bleeding or minor bleeding as per Platelet Inhibition and Patient Outcomes criteria. A higher incidence of clinically significant bleeding was documented in relation to treatment with standard-dose ticagrelor vs clopidogrel in these patients. As this study was underpowered to form any conclusion about efficacy, caution is recommended while interpreting the numerically higher incidence of ischemic events.